
STALLERGENES GREER ANNOUNCES COLLABORATION WITH THE SEAN N. PARKER CENTER FOR ALLERGY AND ASTHMA RESEARCH AT STANFORD UNIVERSITY**DATE: November 14, 2016**

London (UK) - Stallergenes Greer (the "Company") (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced a collaboration with the Sean N. Parker Center for Allergy and Asthma Research at Stanford University ("Stanford") to identify potential biomarkers of Allergy Immunotherapy (AIT) efficacy.

The primary goal of the collaboration is to assess the impact of peanut oral immunotherapy on biological parameters. It includes the evaluation of the Company's proprietary biomarkers in peanut-allergic patients treated with oral immunotherapy as well as the comparative analysis through non-hypothesis driven approaches of responders versus non-responders to peanut oral immunotherapy.

Despite significant advances in recent years, there is still a need to identify biological parameters which could be used to select patients likely to benefit the most from AIT – the only etiologic treatment for allergic respiratory diseases – and to objectively measure clinical responses throughout the course of treatment. In the context of the emerging trends of precision medicine, biomarkers will potentially assist physicians in managing allergic patients in a more optimal way.

"This collaboration with the Sean N. Parker Center for Allergy and Asthma Research at Stanford University will provide us with access to a world-class research which will help us find new treatment options for allergic patients," said Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer. "This work has the potential to confirm the relevance of novel, predictive or follow-up biomarker candidates for a variety of clinical applications in allergy."

Terms of the agreement were not disclosed.

ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2015 annual report published on 29 April 2016 on the Company's website (www.stallergenesgreer.com). Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

Contacts:

Investor and analyst relations

Peter Bühler

Chief Financial Officer

Tel: +33 1 55 59 23 22

Email: investorrelations@aresallergyco.com

Media relations

Lise Lemonnier

Head of Global Communications

Tel: + 33 1 55 59 20 96

Email: llemonnier@stallergenes.com

Investor relations agency

FTI Consulting

Arnaud de Cheffontaines

Tel: +33 1 47 03 69 48

Email:

arnaud.decheffontaines@fticonsulting.com

Media relations agency

Havas Worldwide Paris

Jean-Baptiste Froville

Tel: +33 1 58 47 95 39

Email: jean-baptiste.froville@havasww.com